We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent (SOGUG-07-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00544609
Recruitment Status : Completed
First Posted : October 16, 2007
Last Update Posted : October 2, 2014
Information provided by (Responsible Party):

October 15, 2007
October 16, 2007
October 2, 2014
December 2007
August 2010   (Final data collection date for primary outcome measure)
  • Safety profile of Sorafenib in combination with Radiotherapy. [ Time Frame: 12 weeks ]
  • Maximum tolerated dose of Sorafenib in combination with Radiotherapy. [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT00544609 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Phase I Trial of Sorafenib in Combination With Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Study phase I in patients with Invasive Bladder Cancer
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Bladder Cancer
  • Drug: Sorafenib
    Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
    Other Name: Nexavar
  • Procedure: Radiotherapy
    3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
    Other Names:
    • Sorafenib
    • Nexavar
2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
  • Drug: Sorafenib
  • Procedure: Radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2012
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients diagnosed with urothelial carcinoma of the bladder, in clinical stages T2-4a N0 M0 (if multifocal evaluation of all lesions by biopsies), who are not candidates for radical cystectomy by medical reasons or refusal.
  • No prior treatment with radiotherapy to the bladder or systemic chemotherapy.
  • Patients must be ≥ 18 years old.
  • Patients must have ECOG performance status 0 to 2.
  • Life expectancy of at least 12 weeks.
  • Patients with adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:

hemoglobin ≥ 9.0 g/dl absolute neutrophil count ≥ 1.500/mm3 platelets ≥ 100.000/mm3. total bilirubin ≤ 1.5 times the upper limit of normality SGOT (AST) and/or SGPT (ALT) ≤ 2.5 times the upper limit of normality alkaline phosphatase ≤ 4 x ULN serum creatinine ≤1.5 upper limit of normality PT-INR/PTT < 1.5 x upper limit of normality creatinine clearance ≥ 40 ml/min using Cockcroft-Gaul

  • Patients must give their written informed consent before any procedure related to the study is performed; therefore, it must be given at the selection visit. The patient must be informed that he has the right to withdraw from the study at any time, without any kind of prejudice.
  • Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions.
  • Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication.
  • Patients from both sexes must use adequate contraceptive methods (oral or injectable contraceptives, intrauterine device, condom, sterilization) whilst participating in the protocol. After the retreat of treatment with sorafenib, the contraceptive methods must be used during 4 weeks in women and during 3 months in men.

Exclusion Criteria:

  • Patients with active infection or other serious medical conditions (autologous bone marrow transplant or stem cell rescue within 4 months of study, patients undergoing renal dialysis, known HIV infection or chronic hepatitis B or C, active clinically serious infections > CTCAE Grade 2, non-healing wound, ulcer, or bone fracture).
  • Abuse of substances, clinical conditions, psychological or social, that would preclude appropriate informed consent or compliance with protocol.
  • Concurrent treatment with other experimental drugs (within 30 days prior to study entry).
  • Concurrent treatment with other anti-cancer- or immunotherapy during the study or within 4 weeks of study entry.
  • Treatment wuth mitomycin C or nitrosureas during 6 weeks prior of study entry.
  • History of prior malignancies within the preceding 5 years other than previously treated basal cell carcinoma of the skin, incipient prostate cancer and in situ cervix carcinoma.
  • Pregnant or breast feeding patients.
  • Known or suspected allergy to sorafenib.
  • Cardiac disease: Congestive heart failure > class II NYHA; active CAD (myocardial infarction more than 6 months to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted).
  • Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management.
  • Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis.
  • Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months.
  • Patients with hydronephrosis.
  • Patients with seizure disorder requiring medication (such as steroids or antiepileptics).
  • History of organ allograft.
  • Patient unable to swallow oral medication.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Spanish Oncology Genito-Urinary Group
Spanish Oncology Genito-Urinary Group
Not Provided
Study Chair: Xavier García del Muro Solans, MD Institut Català d' Oncología, Barcelona
Study Chair: Salvador Villà Freixa, MD Institut Català d' Oncología, Barcelona
Spanish Oncology Genito-Urinary Group
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP